Wereport a case of dilated cardiomyopathy with hyperthyroidism. A 28-year-old man was admitted because of congestive heart failure and atrial fibrillation, and was newly diagnosed as having hyperthyroidism. Despite administration of antithyroid medication, he developed recurrent congestive heart failure. An echocardiogram revealed a moderately dilated left ventricle with diffuse hypokinesis. Though his thyroid function normalized, the patient's cardiac dysfunction did not improve. Beta-blocker therapy was begun with subsequent improvement in clinical symptoms. This suggests that beta-blocker treatment may be effective in patients with atrial fibrillation associated with cardiomyopathy and hyperthyroidism. (Internal Medicine 34: 762-767, 1995) 
Introduction
The term "thyroid heart disease" is restricted to patients in whomhyperthyroidism is associated with recurrent paroxysmal or established atrial fibrillation, or congestive heart failure (1) . Generally, cardiac function returns to normal and clinical signs and symptomsresolve in the majority of patients with thyrotoxic heart disease after treatment of the thyroid condition (2) . It is rare for cardiac dysfunction to persist after the patient becomes euthyroid unless pre-existing cardiac disease is present (3) . Wereport herein a case of thyrotoxic heart disease with dilated cardiomyopathy (DCM) which showed persistence of heart failure despite improvement in thyroid function. Administration of beta-blocker therapy resulted in improvementof clinical symptoms.
Case Report
A 28-year-old man presented with a one-year history of a fine tremor of the hands and weight loss. He began to develop weight gain and exertional dyspnea in October 1991 and, at a local hospital, was diagnosed as having hyperthyroidism, congestive heart failure, and atrial fibrillation. He was admitted to the local hospital and became well. But after his discharge, he did not go to the hospital for several days. He first visited our hospital for further investigation in November 1 99 1 and showed NewYork Heart Association (NYHA)class II. In January 1992, he began to complain of facial edema, and recurrent weight gain and dyspnea on exertion. This led to admission to our hospital for treatment ofcongestive heart failure on January 31. His mother had diabetes mellitus and chronic thyroiditis, but additional family history was unremarkable. Upon admission, a physical examination showed his blood pressure to be 1 12/62 mmHg,and his pulse to be irregular at 120/min. His height was 170 cm, andhis weightwas 80 kg. No anemia, jaundice, or exophthalmos was observed. A goiter was palpable. The jugular vein was distended. No heart murmuror rales were noted. The liver was palpable 2 cm below the right costal margin. Edema was present in both lower limbs. He was classified as having NYHAclass IV congestive heart failure.
Laboratory findings on admission are shown in Table 1 difficult to control his heart failure. Then nipradilol, a betablocker, (3 mg, once daily) was begun on April 28, 1992. After the administration of nipradilol, the average ventricular rate of atrial fibrillation decreased to 60-70/min. VPCs also decreased and disopyramide was stopped at the end of June 1992. His symptoms gradually improved to NYHA class II in August 1992. Cardiac catheterization was performed in August 12, 1 992. It showed marked left ventricular dilatation and diffusely reduced contractility (Fig. 3) . The patient's coronary arteries were without disease. Left ventricular biopsy was performed.
Light microscopic examination demonstrated hypertrophic and loosely associated cardiac muscle fibers with vacuolar changes, degenerate nuclei, and interstitial fibrosis. Electron microscopy showed degeneration and hypertrophy of cardiac muscle fibers, disruption of Z bands, a marked variety of mitochondrial sizes, accumulationof mitochondriaunder the muscle sheath, and a high degree of cardiac muscle fiber degeneration (Fig. 4) . In December 1992, his symptoms improved to NYHA class I and he was able to return to his work. Cardiotonic drugs (proscillaridin and denopamine) could be stopped in March 1994. Though a two-dimensional echocardiogram still revealed a dilated left ventricular cavity with diffuse hypokinesis, in an M-modeechocardiogram, calculated by ten beats, LAD became 41 mmfrom 42 mm, Dd became 60 mmfrom 66 mm, and Ds became 48 mmfrom 58 mmand his CTR improved to 57% in April 1994 (Fig. Id) . He has never returned to sinus rhythm and atrial fibrillation still remained. In June 1994, he was still in NYHAclass I on nipradilol treatment 25 months after therapy was initiated.
Discussion
One could view this as a case of hyperthyroidism combined with DCM.Generally, in the absence of preexisting cardiac disease, treatment ofthyrotoxicosis results in a return of normal cardiac function in patients with thyrotoxic heart disease ( 1 , 4-6) . Most are, especially in younger patients, reverted from atrial fibrillation to sinus rhythm and remain in it when the euthyroid state is attained (2) . Congestive heart failure develops most frequently in older age groups with hyperthyroidism (1, 3) . However, in this young male patient, his heart failure and atrial fibrillation persisted after his thyroid function normalized.
These factors support a dual diagnosis of DCMand hyperthyroidism. Alternatively, it is possible to interpret this as a case of secondary cardiomyopathy, caused by long-term hyperthy- roidism. Kasper et al (7) reported that DCMwas due to hyperthyroidism in four patients of the 673 patients who were evaluated for congestive heart failure. Sandier and Wilson (8) showed that experimentally induced hyperthyroidism in animals produces focal round cell infiltration and focal areas of fibrosis in the myocardium in addition to myocardial hypertrophy. And myocardial hypertrophy has been observed in the hearts of some patients with hyperthyroidism who have no underlying heart disease (9) . Though this patient showed a DCM-likestate, several studies on the long-term prognosis of the patients with hypertrophic cardiomyopathy have shown a DCM-like state characterized by left ventricular cavity enlargement, wall thinning or generalized hypokinesis (10) (11) (12) (13) (14) . Thus the persistence of hyperthyroidism may cause damage to the heart muscle and subsequently cause hypertrophic cardiomyopathy and then progress to a DCM-like state. It is evident from somecase reports that auricular fibrillation per se mayproduce cardiac dilatation and progress to congestive heart failure in patients with otherwise normal hearts (15-1 8) . Andmoreover, atrial fibrillation is often a major contributor to the pathogenesis of heart failure in hyperthyroidism. Ventricular diastolic filling may be compromised by the loss of coordinated atrial contraction and by shortening the diastolic interval when there is a rapid ventricular response (6). In the present patient, nipradilol was shownto be effective in controlling the ventricular rate and thus his symptomsmayhave been improved.
Activation of the sympathetic nervous system has been regarded as an important compensatory mechanism, assisting maintenance of myocardial contractility in severe heart failure. However, recent findings suggest that increased catecholamine levels are linked to decreased beta-adrenergic receptor density and myocardial damage. Beta-adrenergic blockade mayameliorate these harmful effects and paradoxically result in improved ventricular performance in patients with cardiomyopathy (19-22). Heilbrunn et al (23) demonstrated that long-term metoprolol therapy is associated with an increase in myocardial beta-receptor density (up-regulation) , significant improvement in resting cardiac output, and improved contractile response to catecholamine stimulation in heart failure due to DCM.In the same way, nipradilol may be effective in the present patient. In summary, a 28-year-old man with DCM combined with hyperthyroidism is reported. Beta-adrenergic blockade was effective in improving his symptoms, decreasing the ventricular rate and reducing VPCs. Further studies are required to evaluate the efficacy, safety and mechanismof action of betablocker therapy in this condition. 
